Ziprasidone: a new atypical antipsychotic

Abstract

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.

A Comprehensive Review of Tic Disorders in Children

“…A randomized, double-blind, placebo-controlled trial of children and adolescents with TS showed that ziprasidone reduced tics significantly and was tolerated well [ 313 ]. Unlike other atypical neuroleptics, ziprasidone does not appear to cause weight gain and extrapyramidal symptoms but is associated with a dose-dependent QTc interval prolongation [ 314 ]. Thus, patients with cardiac arrhythmia risk should avoid ziprasidone therapy.…”

The Child with Tics or Other Common Movement Disorders

“…A randomized, double-blind, placebo-controlled trial of children and adolescents with TS showed that ziprasidone reduced tics significantly and was tolerated well (Sallee et al 2000). Unlike other atypical neuroleptics, ziprasidone does not appear to cause weight gain and extrapyramidal symptoms but is associated with a dosedependent QTc interval prolongation (Keck et al 2001). Thus, patients with cardiac disease should avoid ziprasidone therapy.…”

“…Tetrabenazine is an FDA-approved medicine for the treatment of chorea associated with Huntington's disease. Open-label clinical studies of patients with TS showed that tetrabenazine improved their tics and TS-related symptoms (Kenney et al 2007;Porta et al 2008). Side-effects of tetrabenazine include drowsiness, sleepiness, akathisia, parkinsonism, and depression, which can be controlled by adjusting the dose (Kaur et al 2016).…”